CLS’ board has extensive experience in the medtech industry and in the commercialization of medtech products, as well as a broad knowledge of oncology, financial markets and economics.
Hans von Celsing, born in 1950
Chairman of the Board since 2013
Education/background: Hans von Celsing, MBA Harvard Business School, was vice president of Elekta (1986-98) and was responsible for major parts of the company’s international marketing efforts, primarily in the US and Asia.
Other assignments: Chairman of the Board of Partner Fondkomission AB, Peptonic Medical AB and ADAM SA. Board member of Advanced Oncotherapy Plc.
Holdings in CLS: 100 000 Class A shares, 432 000 Class B shares and 174 000 warrants.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
Sandy Brandmeier, born in 1961
Member of the Board since 2021
Education/background: Sandy Brandmeier, MBA, has extensive experience from the medical device industry through leading management positions in GE Healthcare, Instrumentarium and Leica Microsystems. Brandmeier is currently President of Sonova, USA. She has extensive knowledge in the launch and establishment of medical devices, especially in the US market.
Other assignments: No other board assignments.
Holdings in CLS: No shares, no warrants.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
Paolo Raffaelli, born in 1965
Member of the Board since 2021
Education / background: Paolo Rafaelli, BSc, MBA, has over 25 years of experience from the medical device industry with international management positions at large American and Swedish companies. In his roles, Raffaelli has commercialized innovative products for minimally invasive therapies in interventional radiology and cardiology. He has also worked with strategic product development.
Other assignments: Board member of Acarix AB 2019-2021.
Holdings in CLS: 20 000 Class B shares and 10 000 warrants.
Dependency: Independent in relation to the company and its management, independent in relation to the company’s major owners.
Lars-Erik Eriksson, born in 1949
Member of the board since 2006
Education/background: Lars-Erik Eriksson, MBA, has long experience from the banking industry, with positions as chief auditor for Sparbankerna in Sweden, as well as for national and international companies of Föreningsbanken. CEO of CLS 2006-2020.
Other assignments: Partner in ED-Consult HB, Chairman of the Board of CLAR Wine AB. Board member of Elano AB and Salitre AB.
Holdings in CLS: 300 000 Class A shares, 748 317 Class B shares and 40 860 warrants via Elano AB.
Dependency: Independent in relation to the company and its management, independent in relation to the company’s major owners.
Marika Crohns, born in 1967
Member of the Board since 2020
Education/background: Marika Crohns, MD, PhD and MBA, is Senior Director of the Sanofi Group, responsible for Medical Affairs, Europe, for oncology, hematology, and transplantation of solid organs. Crohns has extensive experience and a wide network of contacts in the field of oncology, both clinically and commercially.
Other assignments: No other board assignments.
Holdings in CLS: 5 714 class B shares and 2 857 warrants.
Dependency: Independent in relation to the company and its management, independent of the company’s major shareholders.
Stephan Dymling
Member of the Board since 2022
Stephan Dymling holds a PhD in ultrasound diagnostics from Lund University and has 30 years of experience in the medical device sector. He has held senior positions in research and development in several start-up companies and was previously head of the Biomedical Engineering department at Lund University Hospital. Chief Technology Officer of CLS 2010-2022.
Other assignments: Board member of BibbInstruments AB, CEO of Allinug AB and CTO of Kongsberg Beam Technology AS
Holdings in CLS: 155 402 Class B shares and 37 161 warrants plus 65 000 class B shares and 25 000 warrants via Allinug.
Dependency: Independent in relation to the company’s management and in relation to the company’s major owners.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
